Teprasiran - Novartis

Drug Profile

Teprasiran - Novartis

Alternative Names: AKIi-5; DGFi; I-5NP; QPI-1002; QPI002; Teprasiran

Latest Information Update: 29 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Quark Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference; Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute kidney injury; Delayed graft function

Most Recent Events

  • 25 May 2018 Phase-III clinical trials in Acute kidney injury (Prevention, In adults, In the elderly) in USA (IV) (NCT03510897)
  • 27 Apr 2018 Quark Pharmaceuticals plans the MAKE phase III trial for Acute Kidney Injury in May 2018 , (NCT03510897)
  • 04 Nov 2017 Positive efficacy data from a phase II trial in Acute kidney injury released by Quark Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top